Dare Bioscience (DARE) PT Set at $3.00 by Maxim Group

Dare Bioscience (NASDAQ:DARE) has been given a $3.00 price target by Maxim Group in a research report issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target indicates a potential upside of 191.26% from the company’s current price.

Separately, ValuEngine raised shares of Dare Bioscience from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd.

Dare Bioscience stock traded up $0.18 during midday trading on Thursday, hitting $1.03. 9,084,109 shares of the stock were exchanged, compared to its average volume of 54,476. Dare Bioscience has a 52 week low of $0.74 and a 52 week high of $3.59. The firm has a market capitalization of $9.72 million, a price-to-earnings ratio of -0.83 and a beta of 2.37.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. As a group, research analysts anticipate that Dare Bioscience will post -1.06 EPS for the current fiscal year.

An institutional investor recently raised its position in Dare Bioscience stock. Citadel Advisors LLC raised its stake in Dare Bioscience Inc (NASDAQ:DARE) by 205.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 106,338 shares of the biotechnology company’s stock after buying an additional 71,470 shares during the quarter. Citadel Advisors LLC owned about 0.93% of Dare Bioscience worth $104,000 at the end of the most recent reporting period. 7.56% of the stock is currently owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply